Alphatec Holdings achieved total revenue of $214 million in the second quarter, representing a 15% year-over-year increase. This strong performance highlights its enduring growth in surgical sales, providing investors with confidence in the company's reaffirmed revenue outlook of approximately $882 million for the year.
Key Highlights
- Alphatec Holdings, Inc. (NASDAQ: ATEC) reported total revenue of $214 million for the quarter ending June 30, 2026, reflecting a strong 15% increase year-over-year.
- Alphatec's surgical revenue increased by $28 million from the previous year, driven by a 20% growth in case volume.
- The company reported a GAAP gross margin of 72.2% and a non-GAAP gross margin of 72.5%, indicating strong financial health and operational efficiency.
Alphatec Holdings, Inc. (NASDAQ: ATEC) reported total revenue of $214 million for the quarter ending June 30, 2026, reflecting a strong 15% increase year-over-year. This performance surpasses the company's adjusted expectations; for the previous quarter, Alphatec had an EPS of $0.00 against a consensus estimate of $-0.02. The growth in revenue primarily stemmed from a 17% increase in surgical revenue, which reached $196 million compared to the same quarter last year.
Such significant advancements underline Alphatec's competitive positioning in the spine surgery market and indicate strong demand for its innovative solutions.
Strong Surgical Revenue Performance
Alphatec's surgical revenue increased by $28 million from the previous year, driven by a 20% growth in case volume. The commitment to innovation and efficiency in its surgical offerings has evidently benefited the company. Surgical revenue now constitutes the majority of its total earnings, supporting the company's strategy to enhance patient outcomes with better technologies and decisions based on data.
By successfully expanding its user base of surgeons by 24%, Alphatec is poised for sustained demand, which speaks volumes about its market penetration and potential for continued revenue growth.
Financial Health and Profitability Metrics
The company reported a GAAP gross margin of 72.2% and a non-GAAP gross margin of 72.5%, indicating strong financial health and operational efficiency. Adjusted EBITDA stood at $36 million, with a margin of 16.8%, reflecting a year-over-year margin expansion of 420 basis points. Ending cash balances were strong, reported at $119 million.
These figures resonate positively with investors, pointing to efficient cost management even amid challenges, and the potential for operational leverage in the upcoming quarters.
Outlook and Future Performance Expectations
Alphatec has reaffirmed its full-year revenue guidance, targeting approximately $882 million, including around $805 million from surgical revenue, which suggests an optimistic growth trajectory with a projected 15% total revenue growth for 2026. The company has also upwardly adjusted its expected adjusted EBITDA from approximately $134 million to about $140 million, reflecting confidence in its operational efficiencies and demand dynamics. With at least $20 million in expected free cash flow, Alphatec's capacity to fund future growth remains strong.
The live webcast scheduled for later today, August 4, 2026, will provide deeper insights into these plans and financial strategies, marking an important moment for interested investors to gauge the company's forward trajectory.
Peers Moving on This News
- Butterfly Network Inc (BFLY) down 1.1%
- AtriCure Inc (ATRC) little changed
- Inspire Medical Systems Inc (INSP) up 1.3%
Analysis based on the Form 8-K filed 4 August 2026; figures verified against the filing and live market data.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...